OncoSec Medical begins phase 2 OMS-104 melanoma trial with TAVO, OPDIVO combo

OncoSec Medical begins phase 2 OMS-104 melanoma trial with TAVO, OPDIVO combo

OncoSec Medical has dosed the first patient in the OMS-104 phase 2 clinical trial, which is evaluating TAVO (tavokinogene telseplasmid) in combination with OPDIVO (nivolumab) as a neoadjuvant therapy for melanoma. TAVO is OncoSec Medical’s intratumoral DNA plasmid-based interleukin-12 (IL-12) therapy, which is intended to be administered using its gene delivery platform (gene electrotransfer). On […]

Olympus to acquire US medical device firm Veran Medical Technologies for $340m

Olympus to acquire US medical device firm Veran Medical Technologies for $340m

Olympus Corporation has signed a deal worth up to $340 million to acquire Veran Medical Technologies (VMT), a Missouri-based provider of advanced medical devices specializing in interventional pulmonology. The Japanese optical products company will carry out the acquisition via its subsidiary Olympus Corporation of the Americas (OCA). It is said to be the latest in […]

CStone Pharmaceuticals strikes $480m worth oncology deal with Pfizer

CStone Pharmaceuticals strikes $480m worth oncology deal with Pfizer

US pharma giant Pfizer has entered into a collaboration deal worth up to $480 million with Chinese biopharma company CStone Pharmaceuticals to address the oncological needs in China. CStone Pharmaceuticals is engaged in developing and commercializing immuno-oncology and precision medicines for cancer patients. The collaboration will be formed between the Chinese firm and Pfizer’s subsidiaries […]

Illumina to take full ownership of cancer screening company GRAIL in $8bn deal

Illumina to take full ownership of cancer screening company GRAIL in $8bn deal

Illumina acquisition of GRAIL : US sequencing company Illumina has agreed to fully acquire California-based cancer screening company GRAIL in a cash and stock deal worth $8 billion. It was Illumina which had established GRAIL in 2016. Subsequently, it was separated as an independent company driven by Illumina’s NGS technology for developing data science and […]

Galera Therapeutics enrolls patients for pancreatic cancer trial of GC4419

Galera Therapeutics enrolls patients for pancreatic cancer trial of GC4419

Galera Therapeutics said that it has wrapped up enrollment of patients for its phase 1b/2a safety and anti-cancer efficacy clinical trial of the combination of avasopasem manganese (GC4419) with stereotactic body radiation therapy (SBRT) in patients having locally advanced pancreatic cancer (LAPC). The US biotech company said that its investigational, selective small molecule superoxide dismutase (SOD) […]

Ascentage, Acerta to evaluate APG-2575, CALQUENCE combo in r/r CLL/SLL

Ascentage, Acerta to evaluate APG-2575, CALQUENCE combo in r/r CLL/SLL

Ascentage Pharma has entered into a clinical collaboration with Acerta Pharma, the hematology research and development center of excellence of AstraZeneca to assess the combination of Bcl-2 and Bruton’s Tyrosine Kinase (BTK) inhibitors in a type of lymphoma. As per the collaboration terms, Ascentage Pharma will sponsor a clinical trial to evaluate the efficacy and […]

1 5 6 7 8 9 13